Table 7.

Characteristics of patients 9 months post-allogeneic hematopoietic stem cell transplantation (HSCT).

Allogeneic-HSCT
Variables		sjTREC/μg DNA (median: 166.36)
		<median	≥median	p
		n(%)/n(%)/n(%)	n(%)/n(%)/n(%)
Age groups	<50/≥50 years old	17 (77.3)/5 (22.7)	26 (89.7)/3 (10.3)	0.268
Sex	Male/female	11 (50)/11 (50)	12 (41.4)/17 (58.6)	0.540
Diagnosis	ALL/AML/MDS	9 (40.9)/12 (54.5)/1 (4.5)	12 (41.4)/15 (51.7)/2 (6.9)	0.932
Treatment for a prior disease	Chemo/chemo plus radio	21 (95.5)/1 (4.5)	28 (96.6)/1 (3.4)	0.999
Bone marrow status before HSCT	MRD/activea/CR	7 (31.8)/1 (4.5)/14 (63.6)	6 (20.7)/2 (6.9)/21 (72.4)	0.650
Time between last chemo/radio and HSCT	≥6 months/<6 months	4 (18.2)/18 (81.8)	5 (17.2)/24 (82.8)	0.999
Conditioning regimen	MAC/RIC	12 (54.5)/10 (45.5)	23 (79.3)/6 (20.7)	0.059
Stem cell source	PBSC/BMSC	10 (45.5)/12 (54.5)	11 (37.9)/18 (62.1)	0.589
Acute-GvHD	Absent/present	10 (45.5)/12 (54.5)	12 (41.4)/17 (58.6)	0.771
Chronic-GvHD	Absent/present	9 (40.9)/13 (59.1)	15 (51.7)/14 (48.3)	0.443
Bacterial infection episodes	Not present/present	7 (31.8)/15 (68.2)	8 (27.6)/21 (72.4)	0.743
CMV infection episodes	Not present/present	1 (4.5)/21 (95.5)	9 (31)/20 (69)	0.030
Fungal infection episodes	Not present/present	21 (99.5)/1 (4.5)	25 (86.2)/4 (13.8)	0.375
Clinical status	Dead/alive	4 (18.2)/18 (81.8)	2 (6.9)/27 (93.1)	0.383
Total	51 (100%)	22 (100)	29 (100)	Not applied

ALL, acute lymphocytic leukemia; AML, acute myeloid leukemia; chemo, chemotherapy; BMSC, bone marrow stem cell; CMV, cytomegalovirus; CR, complete response; GvHD, graft-versus-host disease; HD, Hodgkin’s disease; HSCT, hematological stem cell transplantation; MAC, myeloablative conditioning; MDS, myelodysplastic syndrome; MRD, minimal residual disease; MM, multiple myeloma; PBSC, peripheral blood stem cell; PR, partial response; radio, radiotherapy; RIC, reduced intensity conditioning; sjTREC, signal joint TREC.

^aActive: three cases of MDS have not received any treatment before HSCT.